Democrats won both chambers on Nov. 3 — and the managed-care tailwind investors were trading was never there: Molina Healthcare's trailing EPS is minus $0.61

• Drug pricing comes first because it is the only item that is already half-built: the administration's most-favored-nation program reached 26 participating manufacturers by the end of August 2026, nine of them added in a single announcement that paired Medicaid price cuts with $19.6 billion of U.S. manufacturing commitments.
• Medicaid restoration is the largest item and the hardest to assemble. The first bill out of the gate, introduced Oct. 1, 2026, restores coverage for nearly 450,000 New Yorkers off the Essential Plan and repeals the premium tax credit eligibility restrictions — a fraction of the $1 trillion at stake.
• The public option is the smallest probability, largest tail. A publicly operated plan in every exchange market would compete for the 20.5 million people still enrolled in the individual market, but it needs 60 votes that do not exist.
• For equities, the practical consequence is that nothing on this list changes a printed quarter before 2028. Oversight, investigations into the administration's drug negotiations, and committee work are what the next twelve months contain.

We view 2026 as a trough for Medicaid margins, with improvement over time as rates incorporate more recent experience.

• Cheaper branded drugs repair the medical cost ratio directly, and the repair lands inside the Medicaid book that Democrats' Medicaid reversal would also refill. Two halves of the agenda, one income statement.
• Rate adequacy is the slow lever: Molina Healthcare's Medicaid premium revenue was flat at $24,175 million for the first nine months of 2026 against $24,174 million a year earlier, so the entire move in Medicaid earnings has come from cost, not price.
• The exchange book is no longer the story. Marketplace is now 267,000 members, 5.5% of the total, and $642 million of a $10,457 million quarterly premium base — which is also why a public option now threatens a slice of the business rather than the franchise.
• The pricing fix is visible where the company controls price: Marketplace medical cost ratio improved to 92.5% in the third quarter of 2026 from 95.6% a year earlier, after a 30% rate increase and the exit of roughly eight of thirteen or fourteen exchange markets.

• Restored subsidies are worth more from a smaller base: the exchange market has already lost 4.6 million members, so the same subsidy dollars now buy a thinner and more price-sensitive book.
• Molina Healthcare has already repriced for this world, raising exchange rates about 30% and telling shareholders it would pull its exchange footprint back to about six states for 2027 from roughly thirteen or fourteen, cutting about $1 billion of premium revenue.
• The timing is the cruel part. Medicaid work requirements and six-month redeterminations take effect Jan. 1, 2027, so the membership trough lands one full year before any restoration can reach a rate filing.
• Which makes the 2028 reopening the single largest date on any of these calendars: the 2027 exchange rate filings due in the summer of 2027 and open enrollment in November 2027 will set the size of the managed-care volume recovery and the hospital payer-mix reversal together.

• A lost policy does not disappear; it reconverts into uncompensated care that hospitals absorb in cash. The review of third-quarter 2026 hospital earnings by the Healthcare Financial Management Association found HCA, Tenet and peers all reporting shifted payer mix and higher uncompensated-care pressure.
• Operating leverage cuts both ways. Tenet Healthcare's enterprise value of $32.3 billion against $22.8 billion of trailing revenue and 5.46 times trailing EBITDA leaves little cushion for a second year of uncompensated-care inflation.
• Restored subsidies are the single largest swing factor on hospital payer mix, and the earliest they can bind is plan year 2028 — a full year after the HCA Healthcare hit has already been booked.
• This is why hospital exposure is the cleanest expression of the election: the loss is quantified, dated and in the printed numbers, and so is the reversal, once a bill lands.

• Novo Nordisk's second quarter already shows the mechanics: revenue rose 2.1% to DKK 78.5 billion while earnings per share fell 20.5% to DKK 4.74. Price did the work; volume did not.
• Eli Lilly shows the counter-case: second-quarter revenue rose 47.7% to $22.974 billion and earnings per share rose 26.3% to $7.96, because volume absorbed the TrumpRx price cut. Which of the two patterns a drugmaker gets depends entirely on whether it has a launch curve or an installed base.
• The pharmacy benefit managers sit between them. Cigna Group's trailing earnings per share of $24.25 and CVS Health's $3.83 are levered to brand-drug spreads, and a government-run TrumpRx channel routes purchases straight to manufacturers, cutting the benefit manager out of a growing share of branded volume.

• A voluntary concession is a price with an expiration date. Statute converts the same discount into a permanent floor, and the consideration each manufacturer received in exchange — tariff relief, U.S. manufacturing commitments, faster market access — was valued as tradable.
• Celltrion's revenue has grown from ₩2.18 trillion in 2023 to ₩5.44 trillion on a trailing basis with operating margin holding at 32.5%, so a lower U.S. price is a margin question rather than a volume question. Its own guidance targets at least ₩600 billion of operating profit in the fourth quarter of 2026.
• Hansoh Pharmaceutical's economics are asymmetric by design: the milestones are earned on U.S. commercialization, where price controls bite, while the Greater China rights it retained sit entirely outside the regime.

• Days to quarters: nothing legislates, so the tradeable variable is the Medicaid margin trough, not the election. Elevance Health's third-quarter 2026 earnings per share of $6.30, up 18.4% from $5.32, is the first hard evidence that 2026 is the bottom.
• Days to quarters: hospitals keep absorbing the exchange loss, so watch uncompensated-care commentary rather than enrollment, and watch 2027 rate notices for signs that a restored exchange market re-enters at viable prices.
• One to three years: managed care gets volume it does not have today, and pharma gets a price floor it cannot negotiate around. Those are opposite trades on opposite dates, and the market has so far priced them on the same day.

• Budget arithmetic: the agenda's two halves pull in opposite directions on the federal ledger, so a package without a credible offset dies in committee rather than on the floor.
• The signature: every bill still needs a president, and a Democratic White House is not guaranteed before 2029 — which leaves the 2028 effective dates contingent on legislation that does not yet exist.
• Payer execution: a restored exchange market re-enters at rates that are not yet filed, and the carriers that re-enter first may end up subsidizing the comeback they spent 2026 running from.
• The falsifier: a 2027 Medicaid rate cycle that funds enrollment rather than margin, or a TrumpRx expansion that routes high-volume specialty medicines away from benefit-manager-reimbursed channels faster than volume can replace the lost spread.